Cancer Treatment

Gastrointestinal stromal tumor (GIST)

4 min read
Image of lungs

Gastrointestinal Stromal Tumor (GIST)

Gastrointestinal stromal tumor (GIST) is a rare type of cancer that develops in the gastrointestinal (GI) tract, which includes the stomach, small intestine, and large intestine. GISTs primarily develop in the connective tissues of these organs and are most commonly found in the stomach. These tumors can be both benign (noncancerous) or malignant (cancerous), with the latter being more common.

Epidemiology

GISTs are relatively rare, accounting for about 1-3% of all GI tumors. The exact cause of GISTs is unknown, but certain genetic mutations have been found to play a role in their development. GISTs can occur at any age, but they are most commonly diagnosed in adults between the ages of 50 and 70. Men and women are equally affected by GISTs.

Diagnosis

The diagnosis of GIST usually involves a combination of imaging tests, such as CT scans or MRIs, and a biopsy. A biopsy is necessary to confirm the presence of GIST and determine whether it is benign or malignant. Genetic testing may also be performed to identify specific mutations that can guide treatment decisions.

Treatment

Treatment options for GIST depend on the size, location, and stage of the tumor, as well as the overall health of the patient. Surgery is the primary treatment for localized GISTs and involves removing the tumor and sometimes a portion of the affected organ. In cases where the tumor has spread to other areas of the body, targeted therapies that specifically inhibit the growth of cancer cells, such as tyrosine kinase inhibitors, are often used. These drugs have shown significant efficacy in GIST treatment and have significantly improved the prognosis for patients with advanced disease.

Now let's explore the most important drugs currently used to treat GIST and the promising future drugs that are in late-stage clinical trials.

Important Drugs Used in GIST Treatment

1. Imatinib (Gleevec): Imatinib is the first-line treatment for patients with unresectable, metastatic, or recurrent GIST. It is a tyrosine kinase inhibitor that blocks the activity of specific proteins that promote tumor growth. Imatinib has shown remarkable effectiveness in the treatment of GISTs, with a response rate of over 80% in clinical trials.

2. Sunitinib (Sutent): Sunitinib is another tyrosine kinase inhibitor approved for the treatment of advanced GISTs that cannot be surgically removed or have become resistant to imatinib. It works by blocking the signaling pathways that drive tumor growth, thereby inhibiting their progression. Sunitinib has demonstrated efficacy in prolonging survival in patients with advanced GIST.

Promising Future Drugs in Late-Stage Clinical Trials

Several new drugs are currently being investigated in late-stage clinical trials for the treatment of GISTs:

  • Ripretinib: Ripretinib is a tyrosine kinase inhibitor that targets a broad spectrum of mutations, including those resistant to imatinib and sunitinib. Phase III trials have shown promising results, leading to its approval by the FDA for the treatment of advanced GIST.
  • Avapritinib: Avapritinib is another tyrosine kinase inhibitor designed to target specific mutations that drive the growth of GISTs, including those resistant to imatinib and sunitinib. Clinical trials have demonstrated its efficacy in patients with advanced GIST.
  • Pexidartinib: Pexidartinib is a selective inhibitor of a protein called CSF1R, which plays a role in promoting tumor growth. It is being investigated in clinical trials for the treatment of advanced GISTs.

These promising drugs offer hope for the future of GIST treatment, particularly for those patients who develop resistance to current therapies or have advanced-stage disease. Continued research and development in this field are crucial to improving outcomes for GIST patients.

In conclusion, Gastrointestinal stromal tumor (GIST) is a rare form of cancer that affects the gastrointestinal tract. Diagnosis often involves imaging tests and biopsies to confirm the presence and nature of the tumor. Treatment options include surgery for localized tumors and targeted therapies, such as imatinib and sunitinib, for advanced GISTs. Ongoing clinical trials are exploring new drugs like ripretinib, avapritinib, and pexidartinib, which show promise in the treatment of GIST.